Live Stock Coverage: Nevro Corp Can’t Burn Your Short Portfolio. Has Another Weak Session

Live Stock Coverage: Nevro Corp Can't Burn Your Short Portfolio. Has Another Weak Session

The stock of Nevro Corp (NYSE:NVRO) is a huge mover today! About 1.46 million shares traded hands or 147.28% up from the average. Nevro Corp (NYSE:NVRO) has risen 17.37% since April 27, 2016 and is uptrending. It has outperformed by 12.15% the S&P500.
The move comes after 9 months negative chart setup for the $2.08B company. It was reported on Nov, 30 by Barchart.com. We have $74.17 PT which if reached, will make NYSE:NVRO worth $62.40 million less.

Analysts await Nevro Corp (NYSE:NVRO) to report earnings on March, 6. They expect $-0.20 earnings per share, up 60.78% or $0.31 from last year’s $-0.51 per share. After $-0.14 actual earnings per share reported by Nevro Corp for the previous quarter, Wall Street now forecasts 42.86% negative EPS growth.

Nevro Corp (NYSE:NVRO) Ratings Coverage

Out of 9 analysts covering Nevro Corp (NYSE:NVRO), 8 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 89% are positive. Nevro Corp has been the topic of 12 analyst reports since August 13, 2015 according to StockzIntelligence Inc. The stock of Nevro Corp (NYSE:NVRO) earned “Overweight” rating by PiperJaffray on Friday, July 22. The rating was initiated by William Blair on Tuesday, July 19 with “Outperform”. The company was maintained on Tuesday, August 9 by JP Morgan. As per Tuesday, March 29, the company rating was initiated by Northland Capital. As per Friday, September 25, the company rating was initiated by BMO Capital Markets. JMP Securities maintained Nevro Corp (NYSE:NVRO) on Tuesday, August 9 with “Market Outperform” rating. The rating was initiated by Piperjaffray with “Overweight” on Friday, July 22.

According to Zacks Investment Research, “Nevro Corp. is a medical device company. It engages in developing and commercializing a neuromodulation platform for the treatment of chronic pain. The Company provides pain relief to the customers suffering from low back pain and types of chronic pains. Nevro has developed and commercialized the Senza (R) spinal cord stimulation (SCS) system for the treatment of chronic pain. Senza, HF10, Nevro and the Nevro logo are trademarks of the company. Nevro Corp. is headquartered in Menlo Park, California.”

Another recent and important Nevro Corp (NYSE:NVRO) news was published by Fool.com which published an article titled: “Why Nevro Corp. Is Up Big Today” on August 09, 2016.

NVRO Company Profile

Nevro Corp., incorporated on October 4, 2006, is a medical device company. The Firm has developed and commercialized a neuromodulation platform for the treatment of chronic pain. The Company’s Senza system is a spinal cord stimulation (SCS) system that delivers its HF10 therapy. HF10 therapy is designed to deliver neuromodulation solutions for treating chronic pain. HF10 therapy offers back pain relief in addition to leg pain relief. HF10 therapy also provides pain relief without paresthesia. HF10 therapy offers benefits to patients, physicians and hospitals.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment